Building on a relationship already in place, Selecta Biosciences is expanding its partnership with French pharma Sanofi to use its in-house technology platform to develop treatments for celiac disease.
The Watertown, Mass-based biotech has developed an immunotherapy platform, dubbed the Synthetic Vaccine Particle platform, or SVP, that is able...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
